Kura Oncology Q3 2026 Results: Net Loss of $70.2M, Loss Narrows
Kura Oncology reported total revenue of $22.8 million for Q3 2026, driven by the introduction of $13.9 million in product revenue. Despite this, the company recorded a net loss of $70.2 million for the quarter and $211.9 million for the first nine months of 2026, with total stockholders' equity declining significantly to $18.0 million from $174.1 million at year-end 2025.
- Key figure
- Net loss $70.2M